Gufic Biosciences Limited
NSE: GUFICBIOPharmaceuticals
Share price
₹406.30
+0.56% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
50
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹4,047 Cr
P/E ratio
55.3
P/B ratio
6.1
ROCE
12.3%
ROE
10.1%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 16.7% over the past year, and 18.1% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales slipped from 19.4% to 16.7% over the last four years.
Whether it grew faster than its sector
It grew 18.1% a year against a sector median of 13.1% — 5.0 percentage points faster.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
It has no steady three-year profit record yet, so growth cannot be weighed against the price.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Gufic Biosciences Limited — this one | — | 55.3× | — |
| Divi's Laboratories | 13%/yr | 83.3× | ₹6.4 |
| Torrent Pharmaceuticals | 22%/yr | 78.7× | ₹3.6 |
| Zydus Lifesciences | 32%/yr | 23.1× | ₹0.72 |
| Laurus Labs Limited | 4%/yr | 98.6× | ₹24.7 |
| Cipla | 10%/yr | 29.6× | ₹3.0 |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Pharmaceuticals), it ranks 78 of 130 on returns, 24 of 127 on growth, 75 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 12.3% on capital, ahead of 40% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the 3 years of cash statements on file it made ₹161 crore of cash from the business but spent ₹211 crore on plant and equipment, ₹50 crore more than it made; the gap was mostly borrowed — borrowings rose from ₹333 crore to ₹405 crore.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 8 checks clear · 88%
Latest result · Q1 FY27
What the last results showed. Whether management kept its word is in Pro.
Revenue up 16% and profit up 72%, with the yearly growth promise raised to 15%-20%
Announced 14 Aug 2026 · Consolidated · Unaudited
Revenue
₹261 Cr
Revenue vs last year
+16.4%
Revenue vs last quarter
+3.5%
Net profit
₹22 Cr
Profit vs last year
+71.6%
Profit vs last quarter
+1.4%
Net margin
8.6%
EPS
₹2.22
Earnings call transcript · 17 Aug 2026
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹4,047 Cr
- Prev close
- ₹406.30
- 52w High
- ₹468
- 52w Low
- ₹268
- Enterprise value
- ₹4,376 Cr
- Beta
- 0.9
- Price CAGR 1y
- 17.0%
- Price CAGR 3y
- 14.0%
- Price CAGR 5y
- 16.0%
- Price CAGR 10y
- 28.0%
Ratios
- Return on assets
- 4.8%
- PEG ratio
- —
- P/E ratio
- 55.3
- P/B ratio
- 6.1
- EV / EBITDA
- 29.5
- Industry P/E
- 38.0
- ROCE
- 12.3%
- ROCE 5y average
- 12.5%
- ROE
- 10.1%
- Debt / Equity
- 0.6
- Interest coverage
- 3.4
- Dividend yield
- 0.0%
- ROE 3y average
- 13.0%
- ROE last year
- 10.0%
Annual P&L
- Annual revenue
- ₹944 Cr
- Annual profit
- ₹64 Cr
- Operating margin
- 16.0%
- Net profit margin
- 6.8%
- EBITDA margin
- 16.0%
- Sales growth 3y
- —
- Sales growth 5y
- —
- Profit growth 3y
- —
- Profit growth 5y
- —
- EPS
- ₹6.4
- Sales growth TTM
- 17.0%
- Profit growth TTM
- 19.0%
- Dividend payout
- 2.0%
Quarter P&L
- Sales latest quarter
- ₹261 Cr
- Profit latest quarter
- ₹22 Cr
- YoY quarterly sales growth
- 16.6%
- YoY quarterly profit growth
- 69.2%
- OPM latest quarter
- 17.9%
Balance Sheet
- Book Value
- ₹66.5
- Face Value
- ₹1.0
- Total debt
- ₹405 Cr
- Total cash
- ₹76 Cr
- Borrowings
- ₹405 Cr
- Reserves / Equity
- 65.5
Cash Flow
- Operating cash flow
- ₹45 Cr
- Free cash flow
- ₹14 Cr
- FCF yield
- -0.6%
- Net cash flow
- ₹46 Cr
Shareholding
- Promoter holding
- 72.5%
- FII holding
- 0.5%
- DII holding
- 3.7%
- Public holding
- 23.4%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | 1,781.00 | 33.8 | 4,27,322 | 0.90 | 2,901.2 | 6.0 | 15,299.9 | 10.5 | 20.5 |
| Divi's Lab. | 9,588.00 | 85.4 | 2,54,531 | 0.31 | 902.0 | 65.5 | 3,080.0 | 27.8 | 22.0 |
| Torrent Pharma. | 4,716.20 | 80.4 | 1,79,389 | 0.81 | 566.0 | 5.8 | 4,921.0 | 54.9 | 15.2 |
| Zydus Lifesci. | 1,153.00 | 23.6 | 1,15,012 | 0.09 | 990.2 | -35.1 | 8,017.0 | 22.0 | 21.1 |
| Laurus Labs | 2,052.80 | 101.4 | 1,10,915 | 0.10 | 362.1 | 125.5 | 2,026.3 | 29.1 | 17.8 |
| Cipla | 1,327.20 | 30.0 | 1,07,221 | 0.98 | 785.6 | -39.2 | 7,119.3 | 2.3 | 15.5 |
| Mankind Pharma | 2,500.00 | 48.4 | 1,03,261 | 0.04 | 574.1 | 29.6 | 4,030.6 | 12.9 | 13.5 |
| Gufic BioScience | 422.55 | 57.7 | 4,237 | 0.02 | 22.3 | 70.7 | 260.8 | 16.6 | 12.3 |
| Median | 417.90 | 34.5 | 2,208 | 0.07 | 13.5 | 29.5 | 164.0 | 18.4 | 15.0 |
Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 |
| Expenses | 176 | 165 | 161 | 167 | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 214 | |
| Material Cost | 123 | 89 | 113 | 99 | 124 | 106 | |||||||
| Change in Inventories | -44 | -2.01 | -35 | -14 | -18 | -5.17 | |||||||
| Purchases of Stock-in-Trade | 11 | 14 | 26 | 16 | 8.93 | 14 | |||||||
| Employee Cost | 36 | 36 | 37 | 40 | 38 | 42 | |||||||
| Other Expenses | 53 | 54 | 57 | 57 | 52 | 57 | |||||||
| Operating Profit | 39 | 36 | 34 | 36 | 39 | 34 | 26 | 33 | 38 | 33 | 47 | 47 | |
| OPM % | 18 | 18 | 18 | 18 | 18 | 19 | 16 | 13 | 15 | 16 | 14 | 19 | 18 |
| Other Income | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 | |
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Interest | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 | |
| Depreciation | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 | |
| Profit before tax | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 17 | 23 | 18 | 29 | 30 | |
| Tax % | 25 | 25 | 26 | 26 | 26 | 26 | 27 | 24 | 26 | 30 | 24 | 26 | |
| Net Profit | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 13 | 17 | 12 | 22 | 22 | |
| EPS in Rs | 2.39 | 2.22 | 2 | 2.08 | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 | |
| Diluted EPS in Rs | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 807 | 820 | 944 | 981 |
| Expenses | 657 | 684 | 793 | 816 |
| Material Cost | 344 | 425 | ||
| Change in Inventories | -25 | -69 | ||
| Purchases of Stock-in-Trade | 55 | 65 | ||
| Employee Cost | 127 | 152 | ||
| Other Expenses | 183 | 220 | ||
| Operating Profit | 150 | 136 | 151 | 165 |
| OPM % | 19 | 17 | 16 | 17 |
| Other Income | -0 | 4 | 3 | 2 |
| Exceptional items (within Other Income) | 0 | 0 | ||
| Interest | 17 | 25 | 37 | 37 |
| Depreciation | 17 | 21 | 31 | 31 |
| Profit before tax | 116 | 94 | 87 | 99 |
| Tax % | 26 | 26 | 26 | |
| Net Profit | 86 | 70 | 64 | 73 |
| EPS in Rs | 8.59 | 6.95 | 6.40 | 7.32 |
| Diluted EPS in Rs | 6.95 | 6.40 | ||
| Dividend Payout % | 1 | 1 | 2 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- —
- 3 years
- —
- TTM
- 17%
Compounded profit growth
- 10 years
- —
- 5 years
- —
- 3 years
- —
- TTM
- 19%
Stock price CAGR
- 10 years
- 28%
- 5 years
- 16%
- 3 years
- 14%
- 1 year
- 17%
Return on equity
- 10 years
- —
- 5 years
- —
- 3 years
- 13%
- Last year
- 10%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 10 | 10 | 10 |
| Reserves | 523 | 591 | 655 |
| Borrowings | 333 | 336 | 405 |
| Other Liabilities | 227 | 232 | 273 |
| Minority Interest | 0 | 0.04 | |
| Total Liabilities | 1,093 | 1,169 | 1,342 |
| Fixed Assets | 159 | 506 | 491 |
| CWIP | 307 | 22 | 22 |
| Investments | 2 | 2 | 2 |
| Other Assets | 625 | 640 | 827 |
| Total Assets | 1,093 | 1,169 | 1,342 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from Operating Activity | -7 | 123 | 45 |
| Cash from Investing Activity | -102 | -71 | -31 |
| Cash from Financing Activity | 82 | -37 | 32 |
| Net Cash Flow | -27 | 15 | 46 |
| Free Cash Flow | -116 | 52 | 14 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 149 | 140 | 115 |
| Inventory Days | 188 | 211 | 281 |
| Days Payable | 156 | 155 | 172 |
| Cash Conversion Cycle | 181 | 197 | 224 |
| Working Capital Days | 97 | 93 | 80 |
| ROCE % | 13 | 12 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
58,52,367inr
2026-03-31
News
News and filings about Gufic Biosciences Limited. Open one to see why it matters.
29 Sept, 19:00 IST · Company event · low impact
Gufic Biosciences Limited — the intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- Active pharmaceutical ingredients & bulk-drug intermediates (antifungals, antibacterials, anaesthetics)
- Botulinum toxin strain / API (Zarbot / Stunnox)
- Dual-chamber IV-bag drug-delivery systems (Technoflex technology)
- Lab chemicals, HPLC/UPLC columns, filters & consumables
- Pharmaceutical packing materials
Depends on the price of
- fuel
Buys drug ingredients from
- BrightGene Bio-Medical Technology (China)
Sells to
- Alkem Laboratories Limited · contract-manufactured lyophilized injectables (CMO)
- Domestic CMO / pharma partners (70+) · lyophilized injectables (contract manufacturing)
- UK National Health Service (NHS) · regulated-market injectables (NHS tender, Navsari supply from FY25-26)
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Classification
- Healthcare › Pharmaceuticals
- ISIN
- INE742B01025
Plants
- Gufic Baroda personal-hygiene facility
- Gufic Belgaum natural-products facility
- Gufic Indore Unit III
- Gufic Navsari Unit I
- Gufic Navsari Unit II
- Gufic Uzbekistan OSD facility
News impact
Big market events that reach Gufic Biosciences Limited, and how the effect spreads.
No recent market events reach this company.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 28 Aug 2026 | unspecified | ₹0.1 |
|---|---|---|
| 22 Sep 2025 | unspecified | ₹0.1 |
| 21 Sep 2023 | unspecified | ₹0.1 |
| 24 Aug 2022 | unspecified | ₹0.1 |
| 9 Sep 2021 | unspecified | ₹0.1 |
| 3 Nov 2020 | unspecified | ₹0.05 |
| 20 Sep 2019 | unspecified | ₹0.05 |
| 19 Sep 2018 | unspecified | ₹0.05 |
Splits, bonuses & buybacks
- daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Earnings call17 Aug 2026
- Annual report · 2025-2612 Aug 2026
- Results presentation30 Jun 2026
- Earnings call1 Jun 2026
- Earnings call · Q3FY2616 Feb 2026
- Annual report · 2024-255 Sep 2025
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.